Next Article in Journal / Special Issue
Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis
Previous Article in Journal / Special Issue
Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 2
Issue 2
10.3390/jof2020019
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Pediatric Invasive Aspergillosis

by
Rachel L. Wattier
* and
Lynn Ramirez-Avila
Department of Pediatrics, Division of Infectious Diseases and Global Health, University of California-San Francisco, 550 16th St, 4th Floor, Box 0434, San Francisco, CA 94143, USA
*
Author to whom correspondence should be addressed.
J. Fungi 2016, 2(2), 19; https://doi.org/10.3390/jof2020019
Submission received: 30 April 2016 / Revised: 6 June 2016 / Accepted: 8 June 2016 / Published: 13 June 2016
(This article belongs to the Special Issue Aspergillus fumigatus: From Diagnosis to Therapy)
Versions Notes

Abstract

:
Invasive aspergillosis (IA) is a disease of increasing importance in pediatrics due to growth of the immunocompromised populations at risk and improvements in long-term survival for many of these groups. While general principles of diagnosis and therapy apply similarly across the age spectrum, there are unique considerations for clinicians who care for children and adolescents with IA. This review will highlight important differences in the epidemiology, clinical manifestations, diagnosis, and therapy of pediatric IA.

1. Introduction

Invasive aspergillosis (IA) is one of the most common and serious infectious complications occurring in immunocompromised children. The incidence of IA appears to be increasing in children as it has in adults [1,2,3,4,5]. Significant advances have occurred in the diagnosis and therapy of IA in the last 15 years, and more recent studies indicate that clinical outcomes have improved during this time period [6,7]. However, treatment success and long-term survival after IA diagnosis remain suboptimal.
The evidence that informs care for children with IA is largely extrapolated from adult studies or based on small non-comparative pediatric studies, predominantly including children with malignancy and/or hematopoietic stem cell transplant (HSCT) recipients. This review will describe the known differences in epidemiology, clinical manifestations, diagnosis and therapy of pediatric IA, and will highlight areas of opportunity for further research.

2. Epidemiology

2.1. Incidence and Vulnerable Populations

The population-based incidence of IA in children is unknown and likely varies across healthcare settings and internationally. According to data from the Kids’ Inpatient Database, a representative dataset of inpatient hospitalizations in the United States, the annual incidence of IA was 437 cases/100,000 (0.4%) hospitalized immunocompromised children in the year 2000 [8]. Among the groups with highest incidence of IA are children severely immunocompromised due to allogeneic HSCT (annual incidence 4.5%), therapy for hematologic malignancies, especially acute myelogenous leukemia (AML; annual incidence 4%), and those with primary immunodeficiencies, particularly chronic granulomatous disease (CGD) (annual incidence 6.5%) [8]. Other populations susceptible to IA include children undergoing solid organ transplantation (SOT) (annual incidence 0.3%), autologous HSCT (annual incidence 0.3%), chemotherapy for solid tumor malignancy (annual incidence 0.1%), and those with advanced acquired immune deficiency syndrome or certain non-malignant hematologic disorders such as bone marrow failure syndromes or hemophagocytic lymphohistiocytosis [6,8,9,10,11]. Additionally, IA has been reported in children with systemic lupus erythematosus receiving high dose corticosteroids and other intensive immunosuppression, and has also rarely been reported in preterm neonates [12,13]. The major predisposing risk factors for IA are similar in adults and children (Table 1), except that risk factors within pediatric SOT recipients are poorly characterized due to limited studies.

2.2. Causative Species

The major causative species of IA are similar in children and adults, with multicenter studies reporting Aspergillus fumigatus as the most commonly identified species, responsible for 53% of cases in the largest pediatric series, followed by A. flavus [6,10,20]. Possibly due to differences in local epidemiology, some single centers have reported a predominance of A. flavus causing invasive disease in children [14,21,22]. This may also be due changes in clinical presentation of pediatric IA over time, since A. flavus is associated with primary cutaneous disease which was a common clinical presentation in early case series [23]. Other commonly reported species in children include A. niger and A. terreus [6,10,22].

2.3. Clinical Outcomes

Although estimates of mortality for children with IA are difficult to compare due to variable timing of outcome assessment, there have been apparent improvements in mortality over the past 15 years. A systematic review from 1995 to 1999 reported a 68% case-fatality rate for IA in patients under 20 years old [24]. Among 66 pediatric patients with cancer and IA diagnosed from 1962 to 1996, 85% died within one year following IA diagnosis [14]. In the largest multi-center study of children with IA, 52.5% of patients diagnosed between 2000 and 2005 died during therapy [10]. More recent pediatric cohort studies that have transitioned to earlier outcome assessments at 12 weeks following diagnosis report lower mortality rates of approximately 30% [5,6,25]. Long term survival of children with IA at a single oncology center improved from 12.5% during 1986–2000 to 58% during 2001–2010 [7,26]. A similar improvement in mortality has been observed in adults with IA [20]. Although this improvement is encouraging, 30% short-term mortality is suboptimal, and IA is associated with other adverse outcomes including prolonged hospitalization, increased hospitalization costs, and interruption in therapy for malignancy [5,8,15].
Risk for poor outcomes among children with IA is driven primarily by host immune status and burden of infection. Children who developed IA in the context of allogeneic HSCT in one study had 6-fold greater odds of death during therapy, compared to those with other underlying conditions [10]. Among children with IA in the context of malignancy, a longer duration of neutropenia following IA diagnosis is associated with increased mortality [27]. Disseminated Aspergillus infection has been associated with increased mortality, and non-pulmonary primary sites, such as cutaneous disease, have been associated with better outcomes [14]. Surgical treatment, though not consistently reported across studies, has been associated with improved survival [10].

3. Clinical Manifestations and Diagnosis

3.1. Clinical Manifestations

Similarly to adults, the lungs are the most commonly affected organ in pediatric IA [3,6,10,11,14,20,21,26,28,29,30,31]. In a review of 139 pediatric IA cases, 80% of children had pulmonary disease, 14% cutaneous, 13% sinus, 8% cerebral, and 4% tracheobronchitis [10]. Although earlier pediatric studies suggested that cutaneous IA is more common in children than adults [21], more recent studies report lower rates of 14%–20%; this is thought to be due in part to the increasing use of central over peripheral venous catheters in pediatric oncology patients [3,10,14]. Cutaneous IA can be primary from direct inoculation or secondary due to hematogenous dissemination from another site [32]. Several case reports describe primary cutaneous IA in preterm neonates [32,33,34].
Disseminated infection, defined as disease occurring in ≥2 sites, has been reported in 10.5% to 38% of children with IA and can be due to hematogenous or contiguous spread [3,7,10,14,21,28]. Aspergillus can be locally invasive, with spread from the lung to the pleura, chest wall, and heart, or from the sinus to the central nervous system (CNS). Although no known studies have been performed, some authors suggest screening children with pulmonary IA for CNS involvement given the high mortality, late appearance of symptoms, and impact on treatment [35]. Uncommon sites of IA include the eye [20], head and neck including otitis media and mastoiditis [26], thyroid [36], and gastrointestinal including liver [3,21,31], heart including endocarditis [37] and pericarditis [26], and bone [14,38].
Although some patients with IA present with isolated fever, the clinical manifestations vary depending on which organ system is involved [14]. Fever is common across all presentations. Patients with pulmonary IA can present with cough, dyspnea, hemoptysis/hemorrhage, hypoxia, and pleuritic symptoms [14,28,29]. Cutaneous IA manifestations can be nonspecific and include erythematous plaques, papules, nodules, pustules, blisters, ecchymosis, and eschar formation, often at sites of prior trauma including intravenous catheter and tape sites [14,21,32]. Facial pain, nasal congestion and discharge, visual changes, and headache have been reported in patients with sinus involvement [11,14,39]. CNS IA can present with changes in mental status, visual disturbances, seizures, and focal neurologic deficits [14].
Atypical presentations without fever also occur [11]. It is also reported that up to 33% of patients with CGD who develop IA are asymptomatic and only 20% are febrile [30]. Patients with CGD, especially those infected with A. nidulans, can develop local extension to the pleura, chest wall, and vertebrae [30]. Unlike neutropenic patients who can suffer from extensive fungal angioinvasion with hematogenous dissemination, IA may cause more locally invasive disease in CGD patients due to an ongoing and ineffective neutrophilic inflammatory response with persistent hyphae [30]. Patients with hyper-IgE syndrome can present with fungal superinfection of pneumatoceles resulting in aspergillomas and subsequent risk for invasion to the lung parenchyma or disseminated disease [30].

3.2. Diagnostic Methods

Although prompt IA diagnosis is important given the high morbidity and mortality associated with this infection, existing modalities, including microbiology, pathology, fungal biomarkers, and radiology, have limitations. With currently available diagnostic methods, many children with suspected invasive mold infections do not have an identified pathogen, and are treated empirically [40]. The median time from onset of symptoms to diagnosis was 11 days (range 0–69 days) in one cohort, reflecting challenges in establishing a diagnosis with currently available methods [14]. Establishment of an optimal diagnostic approach is limited by few pediatric IA diagnostic studies, and inconsistent application of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) classifications of proven and probable IA across different studies [41,42]. Further studies in high-risk pediatric patients are needed to establish the ideal timing, frequency, and combination of tests that result in earlier diagnosis.

3.2.1. Culture and Histopathology

Although culture from a sterile site and histopathologic evidence of tissue invasion remain the gold standard for diagnosis of IA, invasive procedures are needed to obtain samples and the diagnostic yield is low. In a pediatric cohort of 193 HSCT patients with fever, respiratory distress, or radiographic findings concerning for an invasive fungal infection (IFI), only 40% of the 101 bronchoalveolar lavages (BAL) performed were diagnostic, all for an infectious etiology, though 94% of the 19 lung biopsies performed yielded a diagnosis [43]. Furthermore, Aspergillus is rarely recovered from blood cultures [3,10,20]. Although the yield is low, positive cultures from affected sites are important because they identify the organism and provide antifungal susceptibilities in this era of emerging resistance even to first-line therapy [44]. Given the low yield of cultures and the morbidity and mortality of invasive procedures, the diagnosis of IA in many patients relies on indirect diagnostics including fungal markers and radiology.

3.2.2. Galactomannan Antigen

Galactomannan is a polysaccharide in the Aspergillus cell wall that is released during fungal growth and can be measured using an enzyme immunoassay. The limited studies evaluating the use of serum galactomannan in children are heterogeneous; some of the studies are single center, focus on those with malignancies and HSCT, use different definitions for IA, antifungal prophylaxis regimens, and galactomannan positivity cut-offs [31,45,46,47,48,49,50,51,52]. Serum galactomannan for prospective screening of high risk patients and diagnosing IA has been studied mostly in immunocompromised adults [45,53,54,55,56]. The sensitivity and specificity of serum galactomannan for the diagnosis of IA in children is similar to adults (Table 2) [55,57]. Although earlier studies reported higher false positivity rates in children than adults [58], more recently, the false positive rate in a pediatric cohort was 5.2% [47]. Preterm neonates have a false positive galactomannan rate as high as 83% [59]. The cause of the high false positive rates in this population are not known but could be secondary to cross-reactivity with Bifidobacterium spp. that is a normal part of the neonatal GI flora and present in formula milk [59,60,61].
Although galactomannan increases with higher infectious burdens [70], it can have reduced sensitivity early in the infection and if the patient is receiving anti-mold therapy [70]. Lower galactomannan sensitivity and specificity has been reported in SOT patients [53]. Possibly due to the lack of angioinvasion, serum galactomannan has reduced sensitivity in patients with CGD [30,71]. In addition to screening and diagnosis, serum galactomannan has been studied as a predictor of clinical response and survival for patients with IA [72,73,74,75].
Galactomannan testing can also be performed on BAL fluid, cerebrospinal fluid (CSF), and urine. BAL galactomannan may be a helpful adjunct for the early diagnosis of IA though cut-off values for positivity have not been firmly established [69,76]. In a retrospective pediatric cohort of immunocompromised and immunocompetent patients, a BAL galactomannan cut-off of ≥0.98 optical density index (ODI) resulted in a sensitivity of proven or probable IA of 78% and specificity of 92% [69]. This BAL cutoff when combined with a serum galactomannan of ≥0.5 ODI yielded a sensitivity of 89% and specificity of 90% for proven or probable IA [69].
Few studies have assessed the utility of CSF galactomannan for the diagnosis of CNS IA and specific cut-off values for positivity have not been established. A recent study of pediatric and adult patients with CNS IA reported a CSF galactomannan sensitivity of 88% and specificity of 96% when using a cut-off of ≥1 ODI [77]. Urine galactomannan has also been studied in children though is associated with high false positive rates [47].

3.2.3. Beta-d-Glucan

1,3-β-d-glucan (BDG) is a nonspecific cell wall component of many fungal pathogens including Aspergillus. A number of adult studies have assessed the performance of BDG in the diagnosis of IFI and specifically IA (Table 2) [62,78,79]. BDG for the diagnosis of IFI in children is limited to a few case reports and studies [46,67,80,81,82]. It has been difficult to establish an optimal positive cut-off for children because they have higher baseline levels than adults [83] and levels can be affected by colonization with Candida spp., among other causes of false positivity (Table 2) [84].

3.2.4. Molecular Diagnostics

Aspergillus polymerase chain reaction (PCR) diagnostics are promising for pediatric IA. In a meta-analysis, the sensitivity of the blood Aspergillus PCR ranged from 84%–88% and the specificity from 75% to 76% [85]; the sensitivity of the BAL Aspergillus PCR ranged from 77% to 80% and specificity from 94% to 95% [85]. Fewer studies have assessed Aspergillus serum and BAL PCR for screening and diagnosis of IA in children [86,46,87,88,89,90]. Another emerging area is serum and BAL molecular diagnostics for identification of the Aspergillus species and the most common mutations that confer azole resistance [91,92]. Aspergillus PCR from the CSF [93], pleural fluid, fresh [94] and formalin-fixed paraffin-embedded tissue [95] has also been studied for the diagnosis of IA.

3.2.5. Emerging Diagnostics

Given the limitations of established diagnostic methods, further investigation has attempted to identify additional non-invasive methods to diagnose IA in early stages. Different fungal organisms causing pulmonary infection are associated with characteristic profiles of volatile secondary metabolites that can be detected in exhaled breath [96]. A recent study showed 94% sensitivity (95% CI, 81%–98%) and 93% specificity (95% CI, 79%–98%) for a combination of exhaled metabolites to identify proven or probable pulmonary IA in a cohort of adults with suspected pulmonary IFI [96]. The lateral-flow device (LFD) is another promising test. This point of care test detects Aspergillus glycoprotein antigen in both serum and BAL has been studied in adult cohorts [97,98]. While these novel diagnostics shows promise, they have not yet been evaluated in children.

3.2.6. Radiology

Plain film and computer tomography (CT) are used for the diagnosis of pulmonary IA, though radiographic findings overlap with those of other IFI. CT has higher sensitivity and specificity for early diagnosis of pulmonary IA [99,100]. Radiographic findings that are described as characteristic in adult pulmonary IA are less common in children. These include the ‘halo sign’ that occurs earlier in the course of infection, as well as cavitation and the ‘air crescent’ sign that occur upon immune reconstitution [10,101,102,103].
More commonly, pediatric patients with pulmonary IA have nodules, masses, peripheral infiltrates, consolidations, and pleural effusions [10,29,101,102,104]. In a retrospective review of pediatric patients with proven or probable pulmonary IA, the most common findings on CT or plain radiograph were nodules (59%) [10]. Nodules were more commonly reported in older compared to younger children (63% ≥13 year-olds vs. 72%, 6–12 year-olds vs. 39%, 0–5 year-olds). Cavities were reported in 25% of patients and a minority of patients had the halo (11%) and air crescent (2%) signs. The reasons for the lower rates of cavitation and the halo and air crescent signs in children are unknown but differences in pathophysiology, immune response, and timing of imaging are possible explanations [10,101,102,103].
Radiographic findings of sinus and CNS IA are nonspecific. Common radiographic findings of sinus IA are mucosal thickening (67%), opacification (48%), and air fluid levels (24%) [10]. Radiographic findings of CNS IA include hypoattenuating lesions on CT and T2 hyperintense lesions on MRI, single or multiple ring enhancing lesions, or dural enhancement abutting sinus disease [105,106].

4. Treatment

During the last 15 years, multiple new antifungals have become available for treatment of IA, expanding options within three different antifungal classes. However, licensing of new antifungals for use in children lags behind adult approvals, and there are important age-specific pharmacokinetic differences. Table 3 summarizes the antifungals with activity against Aspergillus, their current pediatric licensing status and evidence and/or consensus guidelines supporting their use in children with IA. Off-label use of medications is common in pediatrics and agents may be commonly used for age groups and/or indications that lack regulatory approval [6,10,107].

4.1. Amphotericin B Formulations (Polyenes)

Amphotericin B exerts fungicidal activity by binding to ergosterol and altering permeability of the fungal cell membrane. It is active against Aspergillus species except for Aspergillus terreus [140]. Conventional amphotericin B deoxycholate was the first available antifungal with activity against Aspergillus, and was for many years the only therapeutic option for IA. Its disadvantages are nephrotoxicity and infusion-related adverse effects. Lipid formulations of amphotericin B are better tolerated with less nephrotoxicity [111,112]. Though they differ from one another and from the parent drug in pharmacokinetics, there is no available evidence showing differences in efficacy between any of the formulations [141]. Differences in tissue distribution should be considered when treating infections at specific sites, such as the CNS, because tissue distribution varies between formulations [142]. Lipid amphotericin B formulations remain options for treatment of patients who are intolerant or unresponsive to voriconazole [138,139]. Their potential advantages include lack of drug interactions and broader spectrum of antifungal activity, for patients in whom IA is not confirmed and other fungi are suspected.

4.2. Triazoles

Triazoles inhibit biosynthesis of ergosterol in the fungal cell membrane, and are fungicidal against Aspergillus [143]. Itraconazole was the first available triazole with activity against Aspergillus, but its use for treatment of IA in children is limited due to unreliable bioavailability [120]. Voriconazole became the first line antifungal for IA based on a clinical trial demonstrating superior efficacy and tolerability of voriconazole compared to amphotericin B deoxycholate among patients 12 years and older with definite or probable IA [119,138]. Survival at 12 weeks of therapy was 70.8% in the voriconazole group compared to 57.9% in the amphotericin B group, and severe drug-related adverse events were less common with voriconazole [119]. Although there are no comparative trials in children with IA under 12 years, voriconazole is recommended as primary therapy for pediatric IA based on pediatric safety data and a non-comparative compassionate use study demonstrating complete or partial response to voriconazole in 45% of children with IA and other IFIs who were refractory to or intolerant of conventional therapy [118,139].
Substantially higher doses of voriconazole are needed in young children (<12 years) to achieve adequate drug exposure [113,114,115,116,117]. This is due to linear voriconazole elimination kinetics in children over a wider range of doses compared to adults and adolescents, who have non-linear elimination kinetics at usual doses [113]. Non-linear kinetics result in large increases in exposure with small dose increases, and can be observed in younger children receiving higher voriconazole doses. Additionally, the oral formulation of voriconazole has lower bioavailability in children (44%–65%) compared to adults (>90%); this may be due to more extensive intestinal first pass metabolism in children [114,115,144].
There is substantial inter-patient variability in voriconazole exposure, partly due to polymorphisms in CYP2C19, and this variability may be greater in children than in adults [113,114,115,116,145]. Therapeutic drug monitoring (TDM) of voriconazole is recommended with a target trough range of 1.0–5.0 mg/L [139]. Correlation of treatment failure with trough levels <1.0 mg/L has been shown in young children as well as adolescents and adults [146,147,148,149]. A recent meta-analysis showed clear associations between therapeutic voriconazole levels and treatment success, and between supra-therapeutic levels and toxicity [150]. Voriconazole TDM has demonstrated benefits in children and adults, by reducing avoidable discontinuation of voriconazole and increasing likelihood of a successful response to therapy [149,151].
The most common adverse events associated with voriconazole include hepatic abnormalities, visual changes, and rash, often attributable to photosensitization [113,115,116,118,119]. Less common but serious toxicities include neurotoxicity (confusion and/or hallucination) and prolongation of the QT interval with associated arrhythmias [116,119,152]. Children receiving voriconazole prophylaxis have developed severe phototoxic skin reactions; the mechanism of this reaction is unknown [153,154]. Long term voriconazole exposure has been associated with acceleration of chronic phototoxicity and increased risk for skin cancers in immunocompromised patients [155]. Long term use of voriconazole has also been associated with elevated serum fluoride levels, with associated skeletal fluorosis and painful osteitis [156,157]. Voriconazole is an inhibitor of CYP3A4, CYP2C19 and CYP2C9 and is therefore subject to multiple drug interactions.
Newer triazole agents, posaconazole and isavuconazole, may serve a greater role for therapy of pediatric IA in the future, but their use is currently limited by a paucity of pediatric data. Although there are no published clinical trials comparing efficacy of posaconazole against voriconazole for IA, it is recommended as an option for salvage therapy in patients ≥13 years of age on the basis of an externally controlled clinical trial in adults and adolescents with IA who were refractory to or intolerant of standard therapy [138,139,158]. It is available in oral suspension, oral tablet and IV formulations. Bioavailability of the oral suspension is unreliable and dependent on food intake [159]. This formulation has undergone limited evaluation in children, with observational studies characterizing pharmacokinetics, safety and efficacy in prophylaxis of invasive mycoses [122,123,124]. Preliminary results of a more extensive pediatric pharmacokinetic study indicate that target concentration attainment with the posaconazole oral suspension is poor, especially in young children [160]. The safety profile of posaconazole appears favorable, and further pharmacokinetic studies are in progress to establish optimal dosing of posaconazole in children, especially with the newer formulations, which are dosed differently than the suspension.
Isavuconazole, the most recently developed triazole, was found to be non-inferior to voriconazole for IA in adults [161]. Its potential advantages over voriconazole include broader spectrum of activity (including activity against mucormycosis), reliable pharmacokinetics, and a favorable safety profile [162]. However, there are currently no data to establish its use in children.

4.3. Echinocandins

Echinocandins inhibit synthesis of 1,3-β-d-glucan in the fungal cell wall and are fungistatic against Aspergillus. Caspofungin and micafungin are the best evaluated in children and have a favorable safety profile across multiple pediatric age groups [126,127,131,132,133]. Caspofungin and micafungin have been evaluated in non-comparative studies for treatment of patients with IA, including small numbers of children, mostly as salvage therapy for patients refractory to or intolerant of other agents [131,136]. Because of their fungistatic activity and lack of robust data for use as primary therapy, the echinocandins are recommended as second line therapy for IA in patients who are intolerant to or refractory to first line agents [138,139].

4.4. Combination Antifungal Therapy

Though not routinely recommended for primary IA therapy, use of combination antifungal therapy is common in both children and adults. Two recent multicenter pediatric cohort studies reported use of combination therapy in 46% and 54% of children with IA [6,10]. In one of these studies, children who received combination therapy were more likely to experience adverse events compared to those treated with monotherapy [6]. A recent clinical trial comparing voriconazole monotherapy to voriconazole and anidulafungin combination therapy for primary therapy of adults with IA showed a trend toward lower mortality with combination therapy (19.3% vs. 27.5% at 6 weeks; p = 0.087) but was underpowered for this primary endpoint [163]. The implications for management of children with IA are uncertain; recent European guidelines propose combination therapy as an option for pediatric IA, but with weak recommendations [139]. Combination therapy deserves further evaluation for safety and efficacy in children, given the major differences in antifungal pharmacology in children and adults.

4.5. Adjunctive Therapies

Colony stimulating factors and other therapies intended to reverse predisposing conditions and augment the immune response to Aspergillus are commonly given to children with IA [6,10,22]. As in adults, their specific contribution to clinical outcomes is uncertain, but an effect is biologically plausible due to the importance of immune reconstitution in recovery from IA. Adoptive transfer of donor-derived pathogen-specific T cells, a strategy used successfully against viral infections in HSCT recipients, is a promising option for IA therapy and is currently in early clinical development [164,165]. Many children with IA undergo surgery for disease control, with indications similar to those in adults; one pediatric study identified an association between surgical treatment and improved survival [10,22].

5. Conclusions

Important differences in diagnosis and treatment exist between adult and pediatric IA. Although there have been advances in the diagnosis, treatment, and outcomes of pediatric IA, challenges remain. Better characterization of IA in pediatric populations, such as those with SOT and primary immunodeficiencies, is needed. The greatest gains are likely to come from optimizing the diagnostic approach to IA, including incorporation of risk stratification, and establishing algorithms to determine which patients may be best evaluated through non-invasive tests, versus those that could benefit from invasive testing. Additional evaluation of combination antifungal therapy and pediatric studies of new antifungals will facilitate broader prophylaxis and treatment options in at-risk children. Novel treatment strategies such as immunotherapy may also play a role in the treatment of pediatric IA. Taken together, improved diagnostic and treatment modalities will enable earlier diagnosis and improve mortality for children with IA.

Acknowledgments

Rachel L. Wattier is supported by an Early Career Award from the Thrasher Research Foundation (TRF11939). Lynn Ramirez-Avila is supported through the UCSF John A. Watson Faculty Scholars Program.

Author Contributions

Rachel L. Wattier prepared the “Epidemiology” and “Treatment” sections. Lynn Ramirez-Avila prepared the “Clinical Presentation and Diagnosis” section. Authors revised the entire manuscript jointly.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. McNeil, M.M.; Nash, S.L.; Hajjeh, R.A.; Phelan, M.A.; Conn, L.A.; Plikaytis, B.D.; Warnock, D.W. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 2001, 33, 641–647. [Google Scholar] [CrossRef] [PubMed]
  2. Rosen, G.P.; Nielsen, K.; Glenn, S.; Abelson, J.; Deville, J.; Moore, T.B. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J. Pediatr. Hematol. Oncol. 2005, 27, 135–140. [Google Scholar] [CrossRef] [PubMed]
  3. Rubio, P.M.; Sevilla, J.; González-Vicent, M.; Lassaletta, A.; Cuenca-Estrella, M.; Díaz, M.A.; Riesco, S.; Madero, L. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study. J. Pediatr. Hematol. Oncol. 2009, 31, 642–646. [Google Scholar] [CrossRef] [PubMed]
  4. Pappas, P.G.; Alexander, B.D.; Andes, D.R.; Hadley, S.; Kauffman, C.A.; Freifeld, A.; Anaissie, E.J.; Brumble, L.M.; Herwaldt, L.; Ito, J.; et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 2010, 50, 1101–1111. [Google Scholar] [CrossRef] [PubMed]
  5. Jain, S.; Kapoor, G. Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center. J. Pediatr. Hematol. Oncol. 2015, 37, e1–e5. [Google Scholar] [CrossRef] [PubMed]
  6. Wattier, R.L.; Dvorak, C.C.; Hoffman, J.A.; Brozovich, A.A.; Bin-Hussain, I.; Groll, A.H.; Castagnola, E.; Knapp, K.M.; Zaoutis, T.E.; Gustafsson, B.; et al. A prospective, international cohort study of invasive mold infections in children. J. Pediatric Infect. Dis. Soc. 2015, 4, 313–322. [Google Scholar] [CrossRef] [PubMed]
  7. Domenech, C.; Leick-Courtois, C.; Picot, S.; Bleyzac, N. Improvement in the outcome of invasive aspergillosis in a pediatric hematology department: A 10-Year review. J Pediatr Hematol Oncol 2015, 37, 560–565. [Google Scholar] [CrossRef] [PubMed]
  8. Zaoutis, T.E.; Heydon, K.; Chu, J.H.; Walsh, T.J.; Steinbach, W.J. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006, 117, e711–e716. [Google Scholar] [CrossRef] [PubMed]
  9. Shetty, D.; Giri, N.; Gonzalez, C.E.; Pizzo, P.A.; Walsh, T.J. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 1997, 16, 216–221. [Google Scholar] [CrossRef] [PubMed]
  10. Burgos, A.; Zaoutis, T.E.; Dvorak, C.C.; Hoffman, J.A.; Knapp, K.M.; Nania, J.J.; Prasad, P.; Steinbach, W.J. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008, 121, e1286–e1294. [Google Scholar] [CrossRef] [PubMed]
  11. Al-Rezqi, A.; Hawkes, M.; Doyle, J.; Richardson, S.E.; Allen, U. Invasive mold infections in iatrogenically immunocompromised children: An eight-yr review. Pediatr. Transplant. 2009, 13, 545–552. [Google Scholar] [CrossRef] [PubMed]
  12. Silva, M.F.; Ribeiro, A.S.; Fiorot, F.J.; Aikawa, N.E.; Lotito, A.P.; Campos, L.M.; Mauad, T.; Silva, C.A. Invasive aspergillosis: A severe infection in juvenile systemic lupus erythematosus patients. Lupus 2012, 21, 1011–1016. [Google Scholar] [CrossRef] [PubMed]
  13. Papouli, M.; Roilides, E.; Bibashi, E.; Andreou, A. Primary cutaneous aspergillosis in neonates: Case report and review. Clin. Infect. Dis. 1996, 22, 1102–1104. [Google Scholar] [CrossRef] [PubMed]
  14. Abbasi, S.; Shenep, J.L.; Hughes, W.T.; Flynn, P.M. Aspergillosis in children with cancer: A 34-year experience. Clin. Infect. Dis. 1999, 29, 1210–1219. [Google Scholar] [CrossRef] [PubMed]
  15. Ducassou, S.; Rivaud, D.; Auvrignon, A.; Verite, C.; Bertrand, Y.; Gandemer, V.; Leverger, G. Invasive fungal infections in pediatric acute myelogenous leukemia. Pediatr. Infect. Dis. J. 2015, 34, 1262–1264. [Google Scholar] [CrossRef] [PubMed]
  16. Benjamin, D.K., Jr.; Miller, W.C.; Bayliff, S.; Martel, L.; Alexander, K.A.; Martin, P.L. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr. Infect. Dis. J. 2002, 21, 227–234. [Google Scholar] [CrossRef] [PubMed]
  17. Marciano, B.E.; Spalding, C.; Fitzgerald, A.; Mann, D.; Brown, T.; Osgood, S.; Yockey, L.; Darnell, D.N.; Barnhart, L.; Daub, J.; et al. Common severe infections in chronic granulomatous disease. Clin. Infect. Dis. 2014, 60, 1176–1183. [Google Scholar] [CrossRef] [PubMed]
  18. Vinh, D.C.; Sugui, J.A.; Hsu, A.P.; Freeman, A.F.; Holland, S.M. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J. Allergy Clin. Immunol. 2010, 125, 1389–1390. [Google Scholar] [CrossRef] [PubMed]
  19. Antachopoulos, C. Invasive fungal infections in congenital immunodeficiencies. Clin. Microbiol. Infect. 2010, 16, 1335–1342. [Google Scholar] [CrossRef] [PubMed]
  20. Steinbach, W.J.; Marr, K.A.; Anaissie, E.J.; Azie, N.; Quan, S.P.; Meier-Kriesche, H.U.; Apewokin, S.; Horn, D.L. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J. Infect. 2012, 65, 453–464. [Google Scholar] [CrossRef] [PubMed]
  21. Walmsley, S.; Devi, S.; King, S.; Schneider, R.; Richardson, S.; Fordjones, L. Invasive Aspergillus infections in a pediatric hospital - a 10-year review. Pediatr. Infect. Dis. J. 1993, 12, 673–682. [Google Scholar] [CrossRef] [PubMed]
  22. Georgiadou, S.P.; Pongas, G.; Fitzgerald, N.E.; Lewis, R.E.; Rytting, M.; Marom, E.M.; Kontoyiannis, D.P. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: A 10-year, single-institution, retrospective study. J. Pediatr. Infect. Dis. Soc. 2012, 1, 125–135. [Google Scholar] [CrossRef] [PubMed]
  23. Bernardeschi, C.; Foulet, F.; Ingen-Housz-Oro, S.; Ortonne, N.; Sitbon, K.; Quereux, G.; Lortholary, O.; Chosidow, O.; Bretagne, S. Cutaneous invasive aspergillosis: Retrospective multicenter study of the French Invasive-Aspergillosis Registry and literature review. Medicine 2015, 94, e1018. [Google Scholar] [CrossRef] [PubMed]
  24. Lin, S.; Schranz, J.; Teutsch, S.M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin. Infect. Dis. 2001, 32, 358–366. [Google Scholar] [CrossRef] [PubMed]
  25. Han, S.B.; Kim, S.; Bae, E.Y.; Lee, J.W.; Yoon, J.-S.; Chung, N.-G.; Cho, B.; Jeong, D.C.; Kang, J.H.; Kim, H.-K.; Lee, D.; Lee, H.S. Clinical features and prognosis of invasive pulmonary aspergillosis in Korean children with hematologic/oncologic diseases. J. Korean Med. Sci. 2015, 30, 1121–1128. [Google Scholar] [CrossRef] [PubMed]
  26. Crassard, N.; Hadden, H.; Piens, M.A.; Pondarrë, C.; Hadden, R.; Galambrun, C.; Pracros, J.P.; Souillet, G.; Basset, T.; Berthier, J.C.; Philippe, N.; Bertrand, Y. Invasive aspergillosis in a paediatric haematology department: A 15-year review. Mycoses 2008, 51, 109–116. [Google Scholar] [CrossRef] [PubMed]
  27. Cakir, F.B.; Cakir, E.; Berrak, S.G.; Uyan, Z.S.; Canpolat, C.; Karakoc, F.; Dagli, E. Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy. Pediatr. Hematol. Oncol. 2010, 27, 422–434. [Google Scholar] [CrossRef] [PubMed]
  28. Groll, A.H.; Kurz, M.; Schneider, W.; Witt, V.; Schmidt, H.; Schneider, M.; Schwabe, D. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999, 42, 431–442. [Google Scholar] [CrossRef] [PubMed]
  29. Wright, J.A.; Bradfield, S.M.; Park, J.R.; Hawkins, D.S. Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases. J. Pediatr. Hematol. Oncol. 2003, 25, 286–291. [Google Scholar] [CrossRef] [PubMed]
  30. Antachopoulos, C.; Walsh, T.J.; Roilides, E. Fungal infections in primary immunodeficiencies. Eur. J. Pediatr. 2007, 166, 1099–1117. [Google Scholar] [CrossRef] [PubMed]
  31. Choi, S.-H.; Kang, E.-S.; Eo, H.; Yoo, S.-Y.; Kim, J.H.; Yoo, K.H.; Sung, K.W.; Koo, H.H.; Kim, Y.-J. Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients. Pediatr. Blood Cancer 2013, 60, 316–322. [Google Scholar] [CrossRef] [PubMed]
  32. Woodruff, C.A.; Hebert, A.A. Neonatal primary cutaneous aspergillosis: Case report and review of the literature. Pediatr. Dermatol. 2002, 19, 439–444. [Google Scholar] [CrossRef] [PubMed]
  33. Rogdo, B.; Kahlert, C.; Diener, P.A.; Micallef, J. Primary cutaneous aspergillosis in a preterm neonate. BMJ Case Rep. 2014, 2014. [Google Scholar] [CrossRef] [PubMed]
  34. Simpson, C.L.; Boos, M.D.; Castelo-Soccio, L. A crusted papule in a premature neonate. Cutaneous fungal infection. JAMA Pediatr. 2015, 169, 1173–1174. [Google Scholar] [CrossRef] [PubMed]
  35. Broenen, E.; Mavinkurve-Groothuis, A.; Kamphuis-van Ulzen, K.; Brüggemann, R.; Verweij, P.; Warris, A. Screening of the central nervous system in children with invasive pulmonary aspergillosis. Med. Mycol. Case Rep. 2014, 4, 8–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Badawy, S.M.; Becktell, K.D.; Muller, W.J.; Schneiderman, J. Aspergillus thyroiditis: First antemortem case diagnosed by fine-needle aspiration culture in a pediatric stem cell transplant patient. Transpl. Infect. Dis. 2015, 17, 868–871. [Google Scholar] [CrossRef] [PubMed]
  37. Kalokhe, A.S.; Rouphael, N.; El Chami, M.F.; Workowski, K.A.; Ganesh, G.; Jacob, J.T. Aspergillus endocarditis: A review of the literature. Int. J. Infect. Dis. 2010, 14, e1040–e1047. [Google Scholar] [CrossRef] [PubMed]
  38. Gamaletsou, M.N.; Rammaert, B.; Bueno, M.A.; Moriyama, B.; Sipsas, N.V.; Kontoyiannis, D.P.; Roilides, E.; Zeller, V.; Prinapori, R.; Taj-Aldeen, S.J.; et al. Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome. J. Infect. 2014, 68, 478–493. [Google Scholar] [PubMed]
  39. Green, K.K.; Barham, H.P.; Allen, G.C.; Chan, K.H. Prognostic factors in the outcome of invasive fungal sinusitis in a pediatric population. Pediatr. Infect. Dis. J. 2016, 35, 384–386. [Google Scholar] [CrossRef] [PubMed]
  40. Mor, M.; Gilad, G.; Kornreich, L.; Fisher, S.; Yaniv, I.; Levy, I. Invasive fungal infections in pediatric oncology. Pediatr. Blood Cancer 2011, 56, 1092–1097. [Google Scholar] [CrossRef] [PubMed]
  41. Ascioglu, S.; Rex, J.H.; de Pauw, B.; Bennett, J.E.; Bille, J.E.; Bille, J.; Crokaert, F.; Denning, D.W.; Donnelly, J.P.; Edwards, J.E.; et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin. Infect. Dis. 2002, 34, 7–14. [Google Scholar] [CrossRef] [PubMed]
  42. De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. Clin. Infect. Dis. 2008, 46, 1813–1821. [Google Scholar] [CrossRef] [PubMed]
  43. Qualter, E.; Satwani, P.; Ricci, A.; Jin, Z.; Geyer, M.B.; Alobeid, B.; Radhakrishnan, K.; Bye, M.; Middlesworth, W.; Della-Letta, P.; et al. A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation. Biol. Blood Marrow Transplant. 2014, 20, 1229–1237. [Google Scholar] [CrossRef] [PubMed]
  44. Verweij, P.E.; Chowdhary, A.; Melchers, W.J.G.; Meis, J.F. Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Clin. Infect. Dis. 2016, 62, 362–368. [Google Scholar] [CrossRef] [PubMed]
  45. Steinbach, W.J.; Addison, R.M.; McLaughlin, L.; Gerrald, Q.; Martin, P.L.; Driscoll, T.; Bentsen, C.; Perfect, J.R.; Alexander, B.D. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr. Infect. Dis. J. 2007, 26, 558–564. [Google Scholar] [CrossRef] [PubMed]
  46. Badiee, P.; Alborzi, A.; Karimi, M.; Pourabbas, B.; Haddadi, P.; Mardaneh, J.; Moieni, M. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J. Infect. Dev. Ctries. 2012, 6, 352–357. [Google Scholar] [CrossRef] [PubMed]
  47. Fisher, B.T.; Zaoutis, T.E.; Park, J.R.; Bleakley, M.; Englund, J.A.; Kane, C.; Arceci, R.J.; Guinan, E.; Smith, F.O.; Luan, X.; et al. Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients. J. Pediatric Infect. Dis. Soc. 2012, 1, 103–111. [Google Scholar] [CrossRef] [PubMed]
  48. Hayden, R.; Pounds, S.; Knapp, K.; Petraitiene, R.; Schaufele, R.L.; Sein, T.; Walsh, T.J. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr. Infect. Dis. J. 2008, 27, 815–819. [Google Scholar] [CrossRef] [PubMed]
  49. Hovi, L.; Saxen, H.; Saarinen-Pihkala, U.M.; Vettenranta, K.; Meri, T.; Richardson, M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr. Blood Cancer 2007, 48, 28–34. [Google Scholar] [CrossRef] [PubMed]
  50. Jha, A.K.; Bansal, D.; Chakrabarti, A.; Shivaprakash, M.R.; Trehan, A.; Marwaha, R.K. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. Mycoses 2013, 56, 442–448. [Google Scholar] [CrossRef] [PubMed]
  51. Gefen, A.; Zaidman, I.; Shachor-Meyouhas, Y.; Avidor, I.; Hakim, F.; Weyl Ben-Arush, M.; Kassis, I. Serum galactomannan screening for diagnosis of invasive pulmonary aspergillosis in children after stem cell transplantation or with high-risk leukemia. Pediatr. Hematol. Oncol. 2015, 32, 146–152. [Google Scholar] [CrossRef] [PubMed]
  52. Dinand, V.; Anjan, M.; Oberoi, J.K.; Khanna, S.; Yadav, S.P.; Wattal, C.; Sachdeva, A. Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children. J. Microbiol. Immunol. Infect. 2016, 49, 66–73. [Google Scholar] [CrossRef] [PubMed]
  53. Pfeiffer, C.D.; Fine, J.P.; Safdar, N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin. Infect. Dis. 2006, 42, 1417–1427. [Google Scholar] [CrossRef] [PubMed]
  54. Leeflang, M.M.; Debets-Ossenkopp, Y.J.; Visser, C.E.; Scholten, R.J.; Hooft, L.; Bijlmer, H.A.; Reitsma, J.B.; Bossuyt, P.M.; Vandenbroucke-Grauls, C.M. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst. Rev. 2008, 8, CD007394. [Google Scholar]
  55. Leeflang, M.M.; Debets-Ossenkopp, Y.J.; Wang, J.; Visser, C.E.; Scholten, R.J.; Hooft, L.; Bijlmer, H.A.; Reitsma, J.B.; Zhang, M.; Bossuyt, P.M.; et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst. Rev. 2015, 12, CD007394. [Google Scholar] [PubMed]
  56. Arvanitis, M.; Anagnostou, T.; Mylonakis, E. Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high-risk hematology patients: A diagnostic meta-analysis. Clin. Infect. Dis. 2015, 61, 1263–1272. [Google Scholar] [CrossRef] [PubMed]
  57. Lehrnbecher, T.; Phillips, R.; Alexander, S.; Alvaro, F.; Carlesse, F.; Fisher, B.; Hakim, H.; Santolaya, M.; Castagnola, E.; Davis, B.L.; et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J. Clin. Oncol. 2012, 30, 4427–4438. [Google Scholar] [CrossRef] [PubMed]
  58. Herbrecht, R.; Letscher-Bru, V.; Oprea, C.; Lioure, B.; Waller, J.; Campos, F.; Villard, O.; Liu, K.L.; Natarajan-Amé, S.; Lutz, P.; et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 2002, 20, 1898–1906. [Google Scholar] [CrossRef] [PubMed]
  59. Siemann, M.; Koch-Dörfler, M.; Gaude, M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 1998, 41, 373–377. [Google Scholar] [CrossRef] [PubMed]
  60. Mennink-Kersten, M.A.; Ruegebrink, D.; Klont, R.R.; Warris, A.; Gavini, F.; Op den Camp, H.J.; Verweij, P.E. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J. Clin. Microbiol. 2005, 43, 3925–3931. [Google Scholar] [CrossRef] [PubMed]
  61. Dornbusch, H.J.; Groll, A.; Walsh, T.J. Diagnosis of invasive fungal infections in immunocompromised children. Clin. Microbiol. Infect. 2010, 16, 1328–1334. [Google Scholar] [CrossRef] [PubMed]
  62. Lamoth, F.; Cruciani, M.; Mengoli, C.; Castagnola, E.; Lortholary, O.; Richardson, M.; Marchetti, O. β-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: A systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3). Clin. Infect. Dis. 2012, 54, 633–643. [Google Scholar] [CrossRef] [PubMed]
  63. Fisher, B.T. The role of biomarkers for diagnosis of and therapeutic decisions related to invasive aspergillosis in children. Curr. Fungal Infect. Rep. 2013, 7, 7–14. [Google Scholar] [CrossRef] [PubMed]
  64. Nucci, M.; Carlesse, F.; Cappellano, P.; Varon, A.G.; Seber, A.; Garnica, M.; Nouér, S.A.; Colombo, A.L. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE 2014, 9, e87784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Marty, F.M.; Koo, S. Role of (1->3)-β-d-glucan in the diagnosis of invasive aspergillosis. Med. Mycol. 2009, 47 (Suppl. 1), S233–S240. [Google Scholar] [CrossRef] [PubMed]
  66. Prattes, J.; Schilcher, G.; Krause, R. Reliability of serum 1,3-β-d-glucan assay in patients undergoing renal replacement therapy: A review of the literature. Mycoses 2015, 58, 4–9. [Google Scholar] [CrossRef] [PubMed]
  67. Goudjil, S.; Kongolo, G.; Dusol, L.; Imestouren, F.; Cornu, M.; Leke, A.; Chouaki, T. (1-3)-β-D-glucan levels in candidiasis infections in the critically ill neonate. J. Matern. Fetal. Neonatal Med. 2013, 26, 44–48. [Google Scholar] [CrossRef] [PubMed]
  68. D’Haese, J.; Theunissen, K.; Vermeulen, E.; Schoemans, H.; De Vlieger, G.; Lammertijn, L.; Meersseman, P.; Meersseman, W.; Lagrou, K.; Maertens, J. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and clinical validity. J. Clin. Microbiol. 2012, 50, 1258–1263. [Google Scholar] [CrossRef] [PubMed]
  69. Desai, R.; Ross, L.A.; Hoffman, J.A. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr. Infect. Dis. J. 2009, 28, 283–286. [Google Scholar] [CrossRef] [PubMed]
  70. Marr, K.A.; Balajee, S.A.; McLaughlin, L.; Tabouret, M.; Bentsen, C.; Walsh, T.J. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J. Infect. Dis. 2004, 190, 641–649. [Google Scholar] [CrossRef] [PubMed]
  71. Blumental, S.; Mouy, R.; Mahlaoui, N.; Bougnoux, M.E.; Debré, M.; Beauté, J.; Lortholary, O.; Blanche, S.; Fischer, A. Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey. Clin. Infect. Dis. 2011, 53, e159–e169. [Google Scholar] [CrossRef] [PubMed]
  72. Han, S.B.; Kim, S.K.; Lee, J.W.; Yoon, J.-S.; Chung, N.-G.; Cho, B.; Jeong, D.C.; Kang, J.H.; Kim, H.-K.; Lee, D.-G.; et al. Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis. BMC Infect. Dis. 2015, 15, 271. [Google Scholar] [CrossRef] [PubMed]
  73. Neofytos, D.; Railkar, R.; Mullane, K.M.; Fredricks, D.N.; Granwehr, B.; Marr, K.A.; Almyroudis, N.G.; Kontoyiannis, D.P.; Maertens, J.; Fox, R.; et al. Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis. PLoS ONE 2015, 10, e0129022. [Google Scholar] [CrossRef] [PubMed]
  74. Miceli, M.H.; Grazziutti, M.L.; Woods, G.; Zhao, W.; Kocoglu, M.H.; Barlogie, B.; Anaissie, E. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications. Clin. Infect. Dis. 2008, 46, 1412–1422. [Google Scholar] [CrossRef] [PubMed]
  75. Bergeron, A.; Porcher, R.; Menotti, J.; Poirot, J.L.; Chagnon, K.; Vekhoff, A.; Cornet, M.; Isnard, F.; Raffoux, E.; Brethon, B.; et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J. Clin. Microbiol. 2012, 50, 823–830. [Google Scholar] [CrossRef] [PubMed]
  76. De Mol, M.; de Jongste, J.C.; van Westreenen, M.; Merkus, P.J.; de Vries, A.H.; Hop, W.C.; Warris, A.; Janssens, H.M. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan. Pediatr. Pulmonol. 2013, 48, 789–796. [Google Scholar] [CrossRef] [PubMed]
  77. Chong, G.M.; Maertens, J.A.; Lagrou, K.; Driessen, G.J.; Cornelissen, J.J.; Rijnders, B.J. Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid. J. Clin. Microbiol. 2016, 54, 428–431. [Google Scholar] [CrossRef] [PubMed]
  78. Odabasi, Z.; Mattiuzzi, G.; Estey, E.; Kantarjian, H.; Saeki, F.; Ridge, R.J.; Ketchum, P.A.; Finkelman, M.A.; Rex, J.H.; Ostrosky-Zeichner, L. β-d-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 2004, 39, 199–205. [Google Scholar] [CrossRef] [PubMed]
  79. Sulahian, A.; Porcher, R.; Bergeron, A.; Touratier, S.; Raffoux, E.; Menotti, J.; Derouin, F.; Ribaud, P. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 2014, 52, 2328–2333. [Google Scholar] [CrossRef] [PubMed]
  80. Mularoni, A.; Furfaro, E.; Faraci, M.; Franceschi, A.; Mezzano, P.; Bandettini, R.; Viscoli, C.; Castagnola, E. High levels of β-D-Glucan in immunocompromised children with proven invasive fungal disease. Clin. Vaccine Immunol. 2010, 17, 882–883. [Google Scholar] [CrossRef] [PubMed]
  81. Koltze, A.; Rath, P.; Schöning, S.; Steinmann, J.; Wichelhaus, T.A.; Bader, P.; Bochennek, K.; Lehrnbecher, T. Beta-D-glucan screening for the detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation. J. Clin. Microbiol. 2015, 53, 2605–2610. [Google Scholar] [CrossRef] [PubMed]
  82. Salvatore, C.M.; Chen, T.K.; Toussi, S.S.; DeLaMora, P.; Petraitiene, R.; Finkelman, M.A.; Walsh, T.J. (1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients. J. Pediatr. Infect. Dis. Soc. 2015. [Google Scholar] [CrossRef] [PubMed]
  83. Smith, P.B.; Benjamin, D.K., Jr.; Alexander, B.D.; Johnson, M.D.; Finkelman, M.A.; Steinbach, W.J. Quantification of 1,3-beta-D-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin. Vaccine Immunol. 2007, 14, 924–925. [Google Scholar] [CrossRef] [PubMed]
  84. Mokaddas, E.; Burhamah, M.H.; Khan, Z.U.; Ahmad, S. Levels of (1→3)-β-d-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species. BMC Infect. Dis. 2010, 10, 292. [Google Scholar] [CrossRef] [PubMed]
  85. White, P.L.; Wingard, J.R.; Bretagne, S.; Löffler, J.; Patterson, T.F.; Slavin, M.A.; Barnes, R.A.; Pappas, P.G.; Donnelly, J.P. Aspergillus polymerase chain reaction: Systematic review of evidence for clinical use in comparison with antigen testing. Clin. Infect. Dis. 2015, 61, 1293–1303. [Google Scholar] [CrossRef] [PubMed]
  86. Armenian, S.H.; Nash, K.A.; Kapoor, N.; Franklin, J.L.; Gaynon, P.S.; Ross, L.A.; Hoffman, J.A. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J. Pediatr. Hematol. Oncol. 2009, 31, 920–926. [Google Scholar] [CrossRef] [PubMed]
  87. Buchheidt, D.; Reinwald, M.; Spiess, B.; Boch, T.; Hofmann, W.-K.; Groll, A.H.; Lehrnbecher, T. Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients - is Aspergillus PCR appropriate? Mycoses 2016, 59, 67–74. [Google Scholar] [CrossRef] [PubMed]
  88. Hummel, M.; Spiess, B.; Roder, J.; von Komorowski, G.; Dürken, M.; Kentouche, K.; Laws, H.J.; Mörz, H.; Hehlmann, R.; Buchheidt, D. Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. J. Med. Microbiol. 2009, 58, 1291–1297. [Google Scholar] [CrossRef] [PubMed]
  89. Reinwald, M.; Konietzka, C.A.; Kolve, H.; Uhlenbrock, S.; Ahlke, E.; Hummel, M.; Spiess, B.; Hofmann, W.-K.; Buchheidt, D.; Groll, A.H. Assessment of Aspergillus-specific PCR as a screening method for invasive aspergillosis in paediatric cancer patients and allogeneic haematopoietic stem cell recipients with suspected infections. Mycoses 2014, 57, 537–543. [Google Scholar] [CrossRef] [PubMed]
  90. Cesaro, S.; Stenghele, C.; Calore, E.; Franchin, E.; Cerbaro, I.; Cusinato, R.; Tridello, G.; Manganelli, R.; Carli, M.; Palù, G. Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases. Mycoses 2008, 51, 497–504. [Google Scholar] [CrossRef] [PubMed]
  91. White, P.L.; Posso, R.B.; Barnes, R.A. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples. J. Clin. Microbiol. 2015, 53, 2115–2121. [Google Scholar] [CrossRef] [PubMed]
  92. Chong, G.-L.; van de Sande, W.W.; Dingemans, G.J.; Gaajetaan, G.R.; Vonk, A.G.; Hayette, M.-P.; van Tegelen, D.W.; Simons, G.F.; Rijnders, B.J. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J. Clin. Microbiol. 2015, 53, 868–874. [Google Scholar] [CrossRef] [PubMed]
  93. Reinwald, M.; Buchheidt, D.; Hummel, M.; Duerken, M.; Bertz, H.; Schwerdtfeger, R.; Reuter, S.; Kiehl, M.G.; Barreto-Miranda, M.; Hofmann, W.K.; Spiess, B. Diagnostic performance of an Aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis. PLoS ONE 2013, 8, e56706. [Google Scholar] [CrossRef] [PubMed]
  94. Reinwald, M.; Spiess, B.; Heinz, W.J.; Heussel, C.P.; Bertz, H.; Cornely, O.A.; Hahn, J.; Lehrnbecher, T.; Kiehl, M.; Laws, H.J.; et al. Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive aspergillosis enhances diagnostic capabilities. J. Clin. Microbiol. 2013, 51, 4178–85. [Google Scholar] [CrossRef] [PubMed]
  95. Babouee Flury, B.; Weisser, M.; Prince, S.S.; Bubendorf, L.; Battegay, M.; Frei, R.; Goldenberger, D. Performances of two different panfungal PCRs to detect mould DNA in formalin-fixed paraffin-embedded tissue: What are the limiting factors? BMC Infect. Dis. 2014, 14, 692. [Google Scholar] [CrossRef] [PubMed]
  96. Koo, S.; Thomas, H.R.; Daniels, S.D.; Lynch, R.C.; Fortier, S.M.; Shea, M.M.; Rearden, P.; Comolli, J.C.; Baden, L.R.; Marty, F.M. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin. Infect. Dis. 2014, 59, 1733–1740. [Google Scholar] [CrossRef] [PubMed]
  97. Held, J.; Schmidt, T.; Thornton, C.R.; Kotter, E.; Bertz, H. Comparison of a novel Aspergillus lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection 2013, 41, 1163–1169. [Google Scholar] [CrossRef] [PubMed]
  98. Miceli, M.H.; Goggins, M.I.; Chander, P.; Sekaran, A.K.; Kizy, A.E.; Samuel, L.; Jiang, H.; Thornton, C.R.; Ramesh, M.; Alangaden, G. Performance of lateral flow device and galactomannan for the detection of Aspergillus species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis. Mycoses 2015, 58, 368–374. [Google Scholar] [CrossRef] [PubMed]
  99. Caillot, D.; Casasnovas, O.; Bernard, A.; Couaillier, J.F.; Durand, C.; Cuisenier, B.; Solary, E.; Piard, F.; Petrella, T.; Bonnin, A.; et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 1997, 15, 139–147. [Google Scholar] [PubMed]
  100. Hauggaard, A.; Ellis, M.; Ekelund, L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol. 2002, 43, 292–298. [Google Scholar] [CrossRef] [PubMed]
  101. Taccone, A.; Occhi, M.; Garaventa, A.; Manfredini, L.; Viscoli, C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr. Radiol. 1993, 23, 177–180. [Google Scholar] [CrossRef] [PubMed]
  102. Thomas, K.E.; Owens, C.M.; Veys, P.A.; Novelli, V.; Costoli, V. The radiological spectrum of invasive aspergillosis in children: A 10-year review. Pediatr. Radiol. 2003, 33, 453–460. [Google Scholar] [PubMed]
  103. Georgiadou, S.P.; Sipsas, N.V.; Marom, E.M.; Kontoyiannis, D.P. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin. Infect. Dis. 2011, 52, 1144–1155. [Google Scholar] [CrossRef] [PubMed]
  104. Ankrah, A.O.; Sathekge, M.M.; Dierckx, R.A.; Glaudemans, A.W. Imaging fungal infections in children. Clin. Transl. Imaging 2016, 4, 57–72. [Google Scholar] [CrossRef] [PubMed]
  105. Vázquez, E.; Lucaya, J.; Castellote, A.; Piqueras, J.; Sainz, P.; Olivé, T.; Sánchez-Toledo, J.; Ortega, J.J. Neuroimaging in pediatric leukemia and lymphoma: Differential diagnosis. Radiographics 2002, 22, 1411–1428. [Google Scholar] [CrossRef] [PubMed]
  106. Prakash, G.; Thulkar, S.; Arava, S.K.; Bakhshi, S. Cerebral Aspergillus infection in pediatric acute lymphoblastic leukemia induction therapy. Indian J. Med. Paediatr. Oncol. 2012, 33, 236–238. [Google Scholar] [PubMed]
  107. Czaja, A.S.; Reiter, P.D.; Schultz, M.L.; Valuck, R.J. Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research. J. Pediatr. Pharmacol. Ther. 2015, 20, 186–196. [Google Scholar] [PubMed]
  108. Sunakawa, K.; Tsukimoto, I.; Tsunematsu, Y.; Honda, M.; Iwai, N.; Maniwa, T.; Haigo, H.; Suzuki, K.; Mori, T. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children. J. Infect. Chemother. 2012, 18, 456–465. [Google Scholar] [CrossRef] [PubMed]
  109. Kolve, H.; Ahlke, E.; Fegeler, W.; Ritter, J.; Jürgens, H.; Groll, A.H. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J. Antimicrob. Chemother. 2009, 64, 383–387. [Google Scholar] [CrossRef] [PubMed]
  110. Wiley, J.M.; Seibel, N.L.; Walsh, T.J. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr. Infect. Dis. J. 2005, 24, 167–174. [Google Scholar] [CrossRef] [PubMed]
  111. Walsh, T.J.; Seibel, N.L.; Arndt, C.; Harris, R.E.; Dinubile, M.J.; Reboli, A.; Hiemenz, J.; Chanock, S.J. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr. Infect. Dis. J. 1999, 18, 702–708. [Google Scholar] [CrossRef] [PubMed]
  112. Sandler, E.S.; Mustafa, M.M.; Tkaczewski, I.; Graham, M.L.; Morrison, V.A.; Green, M.; Trigg, M.; Abboud, M.; Aquino, V.M.; Gurwith, M.; et al. Use of amphotericin B colloidal dispersion in children. J. Pediatr. Hematol. Oncol. 2000, 22, 242–246. [Google Scholar] [CrossRef] [PubMed]
  113. Walsh, T.J.; Karlsson, M.O.; Driscoll, T.; Arguedas, A.G.; Adamson, P.; Saez-llorens, X.; Vora, A.J.; Arrieta, A.C.; Blumer, J.; Lutsar, I.; et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 2004, 48, 2166–2172. [Google Scholar] [CrossRef] [PubMed]
  114. Karlsson, M.O.; Lutsar, I.; Milligan, P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 2009, 53, 935–944. [Google Scholar] [CrossRef] [PubMed]
  115. Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother. 2010, 54, 4116–4123. [Google Scholar] [CrossRef] [PubMed]
  116. Driscoll, T.A.; Yu, L.C.; Frangoul, H.; Robert, A.; Nemecek, E.; Blumer, J.; Arrieta, A.; Graham, M.L.; Bradfield, S.M.; Baruch, A.; Krance, R.A. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob. Agents Chemother. 2011, 55, 5770–5779. [Google Scholar] [CrossRef] [PubMed]
  117. Friberg, L.E.; Ravva, P.; Karlsson, M.O.; Liu, P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob. Agents Chemother. 2012, 56, 3032–3042. [Google Scholar] [CrossRef] [PubMed]
  118. Walsh, T.J.; Lutsar, I.; Driscoll, T.; Dupont, B.; Roden, M.; Ghahramani, P.; Hodges, M.; Groll, A.H.; Perfect, J.R. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 2002, 21, 240–248. [Google Scholar] [CrossRef] [PubMed]
  119. Herbrecht, R.; Denning, D.W.; Patterson, T.F.; Bennett, J.E.; Greene, R.E.; Oestmann, J.W.; Kern, W.V.; Marr, K.A.; Ribaud, P.; Lortholary, O.; et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002, 347, 408–415. [Google Scholar] [CrossRef] [PubMed]
  120. De Repentigny, L.; Ratelle, J.; Leclerc, J.M.; Cornu, G.; Sokal, E.M.; Jacqmin, P.; De Beule, K. Repeated dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob. Agents Chemother 1998, 42, 404–408. [Google Scholar] [PubMed]
  121. Krishna, G.; Sansone-Parsons, A.; Martinho, M.; Kantesaria, B.; Pedicone, L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 2007, 51, 812–818. [Google Scholar] [CrossRef] [PubMed]
  122. Döring, M.; Müller, C.; Johann, P.D.; Erbacher, A.; Kimmig, A.; Schwarze, C.P.; Lang, P.; Handgretinger, R.; Müller, I. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect. Dis. 2012, 12, 263. [Google Scholar] [CrossRef] [PubMed]
  123. Bernardo, V.A.; Cross, S.J.; Crews, K.R.; Flynn, P.M.; Hoffman, J.M.; Knapp, K.M.; Pauley, J.L.; Molinelli, A.R.; Greene, W.L. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann. Pharmacother. 2013, 47, 976–983. [Google Scholar] [CrossRef] [PubMed]
  124. Döring, M.; Eikemeier, M.; Cabanillas Stanchi, K.M.; Hartmann, U.; Ebinger, M.; Schwarze, C.P.; Schulz, A.; Handgretinger, R.; Müller, I. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 1189–1200. [Google Scholar] [CrossRef] [PubMed]
  125. Lehrnbecher, T.; Attarbaschi, A.; Duerken, M.; Garbino, J.; Gruhn, B.; Kontny, U.; Lüer, S.; Phillips, R.; Scholz, J.; Wagner, H.J.; et al. Posaconazole salvage treatment in paediatric patients: A multicentre survey. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29, 1043–1045. [Google Scholar] [CrossRef] [PubMed]
  126. Walsh, T.J.; Adamson, P.C.; Seibel, N.L.; Flynn, M.; Neely, M.N.; Schwartz, C.; Shad, A.; Kaplan, S.L.; Roden, M.M.; Stone, J.A.; et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 2005, 49, 4536–4545. [Google Scholar] [CrossRef] [PubMed]
  127. Neely, M.; Jafri, H.S.; Seibel, N.; Knapp, K.; Adamson, P.C.; Bradshaw, S.K.; Strohmaier, K.M.; Sun, P.; Bi, S.; Dockendorf, M.F.; et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob. Agents Chemother. 2009, 53, 1450–1456. [Google Scholar] [CrossRef] [PubMed]
  128. Zaoutis, T.; Lehrnbecher, T.; Groll, A.H.; Steinbach, W.J.; Jafri, H.S.; Maertens, J.; Ngai, A.L.; Chow, J.W.; Taylor, A.F.; Strohmaier, K.M.; et al. Safety experience with caspofungin in pediatric patients. Pediatr. Infect. Dis. J. 2009, 28, 1132–1135. [Google Scholar] [CrossRef] [PubMed]
  129. Li, C.; Sun, P.; Dong, Y.; Bi, S.; Desai, R.; Dockendorf, M.F.; Kartsonis, N.A.; Ngai, A.L.; Bradshaw, S.; Stone, J.A. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob. Agents Chemother. 2011, 55, 2098–2105. [Google Scholar] [CrossRef] [PubMed]
  130. Groll, A.H.; Attarbaschi, A.; Schuster, F.R.; Herzog, N.; Grigull, L.; Dworzak, M.N.; Beutel, K.; Laws, H.J.; Lehrnbecher, T. Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey. J. Antimicrob. Chemother. 2006, 57, 527–535. [Google Scholar] [CrossRef] [PubMed]
  131. Zaoutis, T.E.; Jafri, H.S.; Huang, L.M.; Locatelli, F.; Barzilai, A.; Ebell, W.; Steinbach, W.J.; Bradley, J.; Lieberman, J.M.; Hsiao, C.C.; et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009, 123, 877–884. [Google Scholar] [CrossRef] [PubMed]
  132. Seibel, N.L.; Schwartz, C.; Arrieta, A.; Flynn, P.; Shad, A.; Albano, E.; Keirns, J.; Lau, W.M.; Facklam, D.P.; Buell, D.N.; et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 2005, 49, 3317–3324. [Google Scholar] [CrossRef] [PubMed]
  133. Hope, W.W.; Seibel, N.L.; Schwartz, C.L.; Arrieta, A.; Flynn, P.; Shad, A.; Albano, E.; Keirns, J.J.; Buell, D.N.; Gumbo, T.; et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 2007, 51, 3714–3719. [Google Scholar] [CrossRef] [PubMed]
  134. Arrieta, A.C.; Maddison, P.; Groll, A.H. Safety of micafungin in pediatric clinical trials. Pediatr. Infect. Dis. J. 2011, 30, e97–e102. [Google Scholar] [CrossRef] [PubMed]
  135. Hope, W.W.; Kaibara, A.; Roy, M.; Arrieta, A.; Azie, N.; Kovanda, L.L.; Benjamin, D.K., Jr. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. Antimicrob. Agents Chemother. 2015, 59, 905–913. [Google Scholar] [CrossRef] [PubMed]
  136. Denning, D.W.; Marr, K.A.; Lau, W.M.; Facklam, D.P.; Ratanatharathorn, V.; Becker, C.; Ullmann, A.J.; Seibel, N.L.; Flynn, P.M.; van Burik, J.A.H.; et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 2006, 53, 337–349. [Google Scholar] [CrossRef] [PubMed]
  137. Benjamin, D.K., Jr.; Driscoll, T.; Seibel, N.L.; Gonzalez, C.E.; Roden, M.M.; Kilaru, R.; Clark, K.; Dowell, J.A.; Schranz, J.; Walsh, T.J. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 2006, 50, 632–638. [Google Scholar] [CrossRef] [PubMed]
  138. Walsh, T.J.; Anaissie, E.J.; Denning, D.W.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Segal, B.H.; Steinbach, W.J.; Stevens, D.A.; et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008, 46, 327–360. [Google Scholar] [CrossRef] [PubMed]
  139. Groll, A.H.; Castagnola, E.; Cesaro, S.; Dalle, J.H.; Engelhard, D.; Hope, W.; Roilides, E.; Styczynski, J.; Warris, A.; Lehrnbecher, T. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014, 15, e327–e340. [Google Scholar] [CrossRef]
  140. Steinbach, W.J.; Perfect, J.R.; Schell, W.A.; Walsh, T.J.; Benjamin, D.K., Jr. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob. Agents Chemother. 2004, 48, 3217–3225. [Google Scholar] [CrossRef] [PubMed]
  141. Hamill, R.J. Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs 2013, 73, 919–934. [Google Scholar] [CrossRef] [PubMed]
  142. Groll, A.H.; Giri, N.; Petraitis, V.; Petraitiene, R.; Candelario, M.; Bacher, J.S.; Piscitelli, S.C.; Walsh, T.J. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 2000, 182, 274–282. [Google Scholar] [CrossRef] [PubMed]
  143. Manavathu, E.K.; Cutright, J.L.; Chandrasekar, P.H. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 1998, 42, 3018–3021. [Google Scholar] [PubMed]
  144. Zane, N.R.; Thakker, D.R. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. Clin. Pharmacokinet. 2014, 53, 1171–1182. [Google Scholar] [CrossRef] [PubMed]
  145. Bartelink, I.H.; Wolfs, T.; Jonker, M.; De Waal, M.; Egberts, T.C.; Ververs, T.T.; Boelens, J.J.; Bierings, M. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob. Agents Chemother. 2013, 57, 235–240. [Google Scholar] [CrossRef] [PubMed]
  146. Neely, M.; Rushing, T.; Kovacs, A.; Jelliffe, R.; Hoffman, J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 2010, 50, 27–36. [Google Scholar] [CrossRef] [PubMed]
  147. Troke, P.F.; Hockey, H.P.; Hope, W.W. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 2011, 55, 4782–4788. [Google Scholar] [CrossRef] [PubMed]
  148. Choi, S.; Lee, S.; Hwang, J.; Lee, S.; Yoo, K.; Sung, K.; Koo, H.; Kim, Y. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr. Blood Cancer 2013, 60, 82–87. [Google Scholar] [CrossRef] [PubMed]
  149. Kang, H.M.; Lee, H.J.; Cho, E.Y.; Yu, K.-S.; Lee, H.; Lee, J.W.; Kang, H.J.; Park, K.D.; Shin, H.Y.; Choi, E.H. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr. Hematol. Oncol. 2015, 32, 557–567. [Google Scholar] [CrossRef] [PubMed]
  150. Luong, M.-L.; Al-Dabbagh, M.; Groll, A.H.; Racil, Z.; Nannya, Y.; Mitsani, D.; Husain, S. Utility of voriconazole therapeutic drug monitoring: A meta-analysis. J. Antimicrob. Chemother. 2016. [Google Scholar] [CrossRef] [PubMed]
  151. Park, W.B.; Kim, N.H.; Kim, K.H.; Lee, S.H.; Nam, W.S.; Yoon, S.H.; Song, K.H.; Choe, P.G.; Kim, N.J.; Jang, I.J.; et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. Clin. Infect. Dis. 2012, 55, 1080–1087. [Google Scholar] [CrossRef] [PubMed]
  152. Aypar, E.; Kendirli, T.; Tutar, E.; Ciftçi, E.; Ince, E.; Ileri, T.; Atalay, S. Voriconazole-induced QT interval prolongation and torsades de pointes. Pediatr. Int. 2011, 53, 761–763. [Google Scholar] [CrossRef] [PubMed]
  153. Bernhard, S.; Kernland Lang, K.; Ammann, R.A.; Lüer, S.; Leibundgut, K.; Diepold, M.; Aebi, C. Voriconazole-induced phototoxicity in children. Pediatr. Infect. Dis. J. 2012, 31, 769–771. [Google Scholar] [CrossRef] [PubMed]
  154. Van Hasselt, J.G.; Van Eijkelenburg, N.K.; Huitema, A.D.; Schellens, J.H.; Schouten-van Meeteren, A.Y. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrob. Agents Chemother. 2013, 57, 2878–2881. [Google Scholar] [CrossRef] [PubMed]
  155. Cowen, E.W.; Nguyen, J.C.; Miller, D.D.; McShane, D.; Arron, S.T.; Prose, N.S.; Turner, M.L.; Fox, L.P. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J. Am. Acad. Dermatol. 2010, 62, 31–37. [Google Scholar] [CrossRef] [PubMed]
  156. Wermers, R.A.; Cooper, K.; Razonable, R.R.; Deziel, P.J.; Whitford, G.M.; Kremers, W.K.; Moyer, T.P. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin. Infect. Dis. 2011, 52, 604–611. [Google Scholar] [CrossRef] [PubMed]
  157. Tarlock, K.; Johnson, D.; Cornell, C.; Parnell, S.; Meshinchi, S.; Baker, K.; Englund, J. Elevated fluoride levels and periostitis in pediatric hematopoeitic stem cell transplant recipients receiving long-term voriconazole. Pediatr. Blood Cancer 2015, 62, 918–920. [Google Scholar] [CrossRef] [PubMed]
  158. Walsh, T.J.; Raad, I.; Patterson, T.F.; Chandrasekar, P.; Donowitz, G.R.; Graybill, R.; Greene, R.E.; Hachem, R.; Hadley, S.; Herbrecht, R.; et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin. Infect. Dis. 2007, 44, 2–12. [Google Scholar] [CrossRef] [PubMed]
  159. Matthias, K.R.; Nix, D.E.; Peloquin, C.A.; Graham, M.L. Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients. Ann. Pharmacother. 2012, 46, e22. [Google Scholar] [CrossRef] [PubMed]
  160. Merck Sharp & Dohme Corp. A study of the safety, tolerance, and pharmacokinetics of oral posaconazole in immunocompromised children. In ClinicalTrials.gov. Bethesda(MD): National Library of Medicine (US). Available online: https://clinicaltrials.gov/ct2/show/results/NCT01716234 NLM Identifier: NCT01716234 (accessed on 1 April 2016).
  161. Maertens, J.A.; Raad, I.I.; Marr, K.A.; Patterson, T.F.; Kontoyiannis, D.P.; Cornely, O.A.; Bow, E.J.; Rahav, G.; Neofytos, D.; Aoun, M.; et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet 2016, 387, 760–769. [Google Scholar] [CrossRef]
  162. Miceli, M.H.; Kauffman, C.A. Isavuconazole: A new broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 2015, 61, 1558–1565. [Google Scholar] [CrossRef] [PubMed]
  163. Marr, K.A.; Schlamm, H.T.; Herbrecht, R.; Rottinghaus, S.T.; Bow, E.J.; Cornely, O.A.; Heinz, W.J.; Jagannatha, S.; Koh, L.P.; Kontoyiannis, D.P.; et al. Combination antifungal therapy for invasive aspergillosis a randomized trial. Ann. Intern. Med. 2015, 162, 81–89. [Google Scholar] [CrossRef] [PubMed]
  164. Perruccio, K.; Tosti, A.; Burchielli, E.; Topini, F.; Ruggeri, L.; Carotti, A.; Capanni, M.; Urbani, E.; Mancusi, A.; Aversa, F.; et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106, 4397–4406. [Google Scholar] [CrossRef] [PubMed]
  165. Papadopoulou, A.; Kaloyannidis, P.; Yannaki, E.; Cruz, C.R. Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges. Crit. Rev. Oncol. Hematol. 2016, 98, 62–72. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Identified Risk Factors for Invasive Aspergillosis in Children.
Table 1. Identified Risk Factors for Invasive Aspergillosis in Children.
Risk FactorComments
Shared by Multiple Groups
Prolonged and severe neutropenia [6,10,14]
High dose corticosteroids [6,10,14]
Other immunosuppression [6,10,14]
Specific to Children with Malignancy
Acute myelogenous leukemia (vs. other malignancies) [11,15]Majority of episodes are diagnosed during intensive phases of therapy [15]
Specific to HSCT a Recipients
Allogeneic transplant (vs. autologous) [8,10,11,16]
Unrelated donor (vs. related donor) [10,11,16]
Cord blood transplant (vs. other stem cell source) [16]
Graft versus host disease [8,10,11,16]
Specific to SOT b Recipients
Lung transplantation (vs. other organ transplants) [4,8,10,11]Other risk factors related to SOT are poorly characterized in children
Specific to Primary Immunodeficiencies
Chronic granulomatous disease [17]Higher risk in lower quartiles of superoxide production [17]
Hyper-IgE syndrome [18]Risk associated with pneumatoceles following bacterial pneumonias [18]
Other severe defects of phagocyte and/or cellular immunitye.g. Severe combined immunodeficiency, Wiskott-Aldrich syndrome [6,10,19]
a Hematopoietic stem cell transplant; b Solid organ transplant.
Table
Table 2. Fungal Biomarkers for Diagnosis of Invasive Aspergillosis.
Table 2. Fungal Biomarkers for Diagnosis of Invasive Aspergillosis.
Biomarker AttributeGalactomannan Antigen (%, 95% CI)1,3-β-d-glucan (%, 95% CI)
Performance in Serum
Sensitivity—Adult a [55,62]78% (70%–85%)62% (48%–73%)
Sensitivity—Pediatric b [55]84% (66%–93%)Unknown
Specificity—Adult a [55,62]85% (78%–91%)91% (83%–95%)
Specificity—Pediatric b [55]88% (60%–97%)Unknown—likely less than adult
Causes of False Positive ResultPiperacillin-tazobactam, other beta lactam antibiotics, Plasmalyte, Fusarium spp., Histoplasma capsulatum, Penicillium spp. [45,60,63,64]Ampicillin-sulbactam, piperacillin-tazobactam, intravenous immunoglobulin, albumin, certain hemodialysis filters, bacteremia [65,66,67]
Performance in BAL c Fluid
Sensitivity—Adult d [68]86%n/a f
Sensitivity—Pediatric e [69]78%n/a
Specificity—Adult d [68]91%n/a
Specificity—Pediatric e [69]92%n/a
a Positivity cut-off ≥0.5 optical density index (ODI); b Subanalysis of 7 pediatric studies within a meta-analysis; 5 studies used a positivity cut-off ≥0.5 ODI, 1 a cut-off ≥1.5 ODI, one did not report cut-off; c BAL; bronchoalveolar lavage; d Positivity cut-off ≥0.8 ODI; e Positivity cut-off ≥0.98 ODI; f Not applicable, test not performed on BAL fluid.
Table
Table 3. Antifungals for Treatment of Invasive Aspergillosis: Pediatric Licensing and Evidence Supporting Use in Children.
Table 3. Antifungals for Treatment of Invasive Aspergillosis: Pediatric Licensing and Evidence Supporting Use in Children.
Class/Agent (Formulation—IV a/PO b)Ages Currently Licensed cPediatric EvidenceClinical Guidelines
Polyenes
Amphotericin B deoxycholate (IV)AllFirst available agent
Liposomal amphotericin B (IV)≥1 monthPK d, safety [108].
Observational cohort study [109]		IDSA d: alternative primary therapy (A-I), salvage therapy (A-II).
ECIL-4 e: 1st line (B-I), 2nd line (B-II)
Amphotericin B lipid complex (IV)AllObservational cohort study [110].
Non-comparative trial (salvage therapy) [111]		IDSA: alternative primary therapy (A-I), salvage therapy (A-II).
ECIL-4: 1st line (B-II), 2nd line (B-II)
Amphotericin B colloidal dispersion (IV)All (no longer commercially available)Non-comparative trial (salvage therapy) [112]IDSA: alternative primary therapy (A-I), salvage therapy (A-II)
Triazoles
Voriconazole (IV, PO)≥12 years gPK, safety [113,114,115,116,117].
Non-comparative trial (salvage therapy) [118].
RCTf including children >12 years [119]		IDSA: primary therapy (A-I).
ECIL-4: first line (A-I), second line for voriconazole-naïve patients (A-I)
Itraconazole (PO)≥18 yearsPK, safety [120]IDSA: salvage therapy (B-II).
ECIL-4: 2nd line (no grade)
Posaconazole (IV, PO)PO: ≥13 years. IV: ≥18 yearsPK, safety [121,122,123,124].
Retrospective cohort study [125]		IDSA: salvage therapy (B-II).
ECIL-4: 2nd line (no grade)
Isavuconazole (IV, PO)≥18 years
Echinocandins
Caspofungin (IV)≥3 monthsPK, safety [126,127,128,129].
Retrospective cohort study [130].
Non-comparative trial (primary & salvage therapy) [131]		IDSA: salvage therapy (B-II).
ECIL-4: 2nd line (A-II)
Micafungin (IV)≥4 monthsPK, safety [132,133,134,135].
Non-comparative trial (salvage therapy) including pediatric patients [136]		IDSA: salvage therapy (B-II).
ECIL-4: 2nd line (no grade)
Anidulafungin (IV)≥18 yearsPK, safety [137]
a IV; intravenous; b PO; oral; c Licensing status by United States Food and Drug Administration; not all drugs are licensed for primary therapy of invasive aspergillosis; voriconazole, isavuconazole, and amphotericin B deoxycholate are licensed for primary therapy; lipid amphotericin B formulations and caspofungin are licensed for salvage therapy in patients who are intolerant or unresponsive to other agents; posaconazole is licensed only for prophylaxis in the United States, but is licensed for salvage therapy by the European Medications Agency. Micafungin and anidulafungin are not licensed for IA but have in vitro activity similar to caspofungin.; d PK; pharmacokinetics; d IDSA; Infectious Diseases Society of America; combined adult and pediatric guidelines, evidence levels based on adult data [138]; e ECIL-4; Fourth European Conference on Infections in Leukemia; pediatric-specific guidelines [139]; f RCT; randomized controlled trial; g Voriconazole is approved by the European Medications Agency for children age 2–11 years.

Share and Cite

MDPI and ACS Style

Wattier, R.L.; Ramirez-Avila, L. Pediatric Invasive Aspergillosis. J. Fungi 2016, 2, 19. https://doi.org/10.3390/jof2020019

AMA Style

Wattier RL, Ramirez-Avila L. Pediatric Invasive Aspergillosis. Journal of Fungi. 2016; 2(2):19. https://doi.org/10.3390/jof2020019

Chicago/Turabian Style

Wattier, Rachel L., and Lynn Ramirez-Avila. 2016. "Pediatric Invasive Aspergillosis" Journal of Fungi 2, no. 2: 19. https://doi.org/10.3390/jof2020019

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop